DGAP-Media / 2019-12-11 / 09:30
MagForce AG: _'NanoTherm School'_ successfully enters its second round with
*Module B*
· _MagForce successfully hosted the second session of its
practice-oriented, unique, multifaceted application training for the use
of the NanoTherm therapy system in treating brain tumors_
· _The NanoTherm School is part of MagForce's commitment to further
optimize the therapy system and educate medical professionals in its use
to provide brain tumor patients with the best care possible in addition to
a broad geographical coverage to provide greater accessibility_
· _Participants included the team of Prof. Dr. med. habil. Jan-Peter
Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus
Clinic in Zwickau, where now MagForce's NanoTherm therapy system is
available_
*Berlin, Germany and Nevada, USA, December 11, 2019* - With "Module B -
Advanced Course 1: - stereotactic Instillation" MagForce AG (Frankfurt,
Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in
the field of nanomedicine focused on oncology, conducted the second round of
its 'NanoTherm School' in November. The application training series was
launched in January 2019 to provide the highest quality of treatment through
ongoing support for physicians and certify surgeons in the use of the
innovative NanoTherm technology. Same as the first session, "Module A - The
Basics", which took place at the end of January 2019, Module B, focusing on
advanced techniques, was met with great excitement from participants.
The _NanoTherm School_ is part of MagForce's roll-out strategy focusing on a
broad geographic coverage to provide greater availability while also
constantly working on further optimizing its therapy system and educating
medical professionals in its use to provide brain tumor patients with the
best care possible. The training concept of _NanoTherm School_ was developed
in close collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver
Grauer, and Dr. Michael Schwake, University Hospital Münster, and PD Dr.
Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen, drawing on their
long-standing experience in the treatment of brain tumor patients with the
NanoTherm therapy system.
Participants again included the team of Prof. Dr. med. habil. Jan-Peter
Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus
Clinic in Zwickau, with whom MagForce entered into a cooperation agreement
in June 2019. Installation of the mobile treatment center was completed in
summer. The NanoActivator is now ready for use at the clinic after receipt
of final approval and and is now available for the treatment of patients
with brain tumors.
*Prof. Dr. med. habil. Jan-Peter Warnke*, Senior Consultant in the
Neurosurgical Clinic at the Paracelsus Clinic in Zwickau*,
*added_"Innovation is extremely important in medicine and has served our
patients well. Obtaining the appropriate training in new technologies and
techniques is a vital part of adopting these advances into our standard
treatment regimens. Practical trainings such as MagForce's NanoTherm School
are therefore very welcomed as they allow neurosurgeons to ease into the
method while developing the necessary skills.__Thanks to the excellent
preparation and support of the MagForce team, as well as the opportunity to
practice NanoTherm therapy in the most practical and extremely
well-structured way, we are well prepared for the use of the therapy system
at our clinic starting immediately. The use of new teaching methods for
advanced technologies helps us to bring outstanding inventions to
patients."_
About _NanoTherm School_
Targeted towards medical professionals working in the fields of
neuro-surgery and neuro-oncology, the _NanoTherm Therapy School_ series aims
at introducing participants to the theoretical knowledge and practical
techniques required to successfully apply MagForce's NanoTherm technology
for the treatment of brain tumors. In practicing their skills with human
specimens, participants are able to familiarize themselves with the
procedures and device usages in a stress-free environment under largely real
operating conditions.
The _NanoTherm School_ is designed in three consecutive modules allowing
participants to gain knowledge and understanding of MagForce's NanoTherm
technology starting from basic application techniques (nanopasting) and
building to advanced techniques and new surgical application forms in the
final module (Module C). The practical section of the course is complemented
by lectures on directly relevant aspects of NanoTherm therapy, as well as
sample preparation and surgical videos. The equipment and facilities used
during the course meet the requirements of today's state-of-the-art surgical
equipment.
*For more information about NanoTherm School, please contact:*
Dipl.-Ing. Tobias Hanitsch (thanitsch@magforce.com)
Marcel Pilz (mpilz@magforce.com)
*About MagForce AG and MagForce USA, Inc.*
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm therapy system enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices for
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and
NanoActivator are trademarks of MagForce AG in selected countries.
*For more information, please visit: www.magforce.com [1].
Get to know our Technology: video (You Tube) [2]
Stay informed and subscribe to our mailing list [3]*
*Disclaimer *
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
*Contact:*
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com
End of Media Release
Issuer: MagForce AG
Key word(s): Health
2019-12-11 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt
(Scale), Stuttgart, Tradegate Exchange
EQS News ID: 932409
End of News DGAP Media
932409 2019-12-11
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=932409&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=932409&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=932409&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 11, 2019 03:30 ET (08:30 GMT)
© 2019 Dow Jones News